CTLA4 and neoplasm: Research results showed that although the combination of MIO and immune ICIs (anti-PD-1 and anti CTLA-4 antibodies) reduced tumor volume in 4T1-luciferase cell-implanted BALB/c mice as compared to the control group, there was no improvement in the overall survival of mice with the treatment.